{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Deferoxamine", "Hearing loss", "Iran", "Meta-analysis", "Systematic review", "Thalassemia major"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "29201313", "DateRevised": {"Year": "2022", "Month": "03", "Day": "11"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.22088/cjim.8.4.239"], "Journal": {"ISSN": "2008-6164", "JournalIssue": {"Volume": "8", "Issue": "4", "PubDate": {"Year": "2017", "Season": "Fall"}}, "Title": "Caspian journal of internal medicine", "ISOAbbreviation": "Caspian J Intern Med"}, "ArticleTitle": "Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis.", "Pagination": {"StartPage": "239", "EndPage": "249", "MedlinePgn": "239-249"}, "Abstract": {"AbstractText": ["Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine.", "This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran's Q test and I<sup>2</sup> index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant.", "A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3% (95% confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6% (95% CI: 5.7-18.8), 14.6% (95% CI: 10.5-20.6) and 9.1% (95% CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001).", "There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatrics, Behbahan Faculty of Medical Sciences, Behbahan, Iran."}], "LastName": "Badfar", "ForeName": "Gholamreza", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nursing Care Research Center in Chronic Disease, School of Nursing and Midwifery, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran."}], "LastName": "Mansouri", "ForeName": "Akram", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Nursing, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Shohani", "ForeName": "Masoumeh", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Endocrinology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran."}], "LastName": "Karimi", "ForeName": "Hamid", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Khalighi", "ForeName": "Zahra", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Student Research Committee, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Rahmati", "ForeName": "Shoboo", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Epidemiology, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Delpisheh", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran."}], "LastName": "Veisani", "ForeName": "Yousef", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran."}], "LastName": "Soleymani", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran."}], "LastName": "Azami", "ForeName": "Milad", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Iran", "MedlineTA": "Caspian J Intern Med", "NlmUniqueID": "101523876", "ISSNLinking": "2008-6164"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Albera R, Pia F, Morra B, et al. Hearing loss and desferrioxamine in homozygous beta-thalassemia. Int J Audiol. 1988;27:207\u201314.", "ArticleIdList": ["3190562"]}, {"Citation": "Azami M, Gheisoori A, Sayehmiri F, Sayehmiri K. Prevalence of hypothyroidism in patients with Beta thalassemia major in Iran: A systematic review and meta-analysis. J Kurdistan Univ Med Sci. 2016;21:104\u201316."}, {"Citation": "Azami M, Tardeh Z, Abangah GH, Sayemiri K. The prevalence of impaired glucose tolerance in patients with thalassemia major in Iran: a systematic review and meta-analysis. J Shahid Sadoughi Uinv Med Sci. 2016;23:912\u201322."}, {"Citation": "Azami M, Sayehmiri K. Prevalence of diabetes mellitus in Iranian patients with thalassemia major: a systematic review and meta-analysis. J Mazandaran Univ Med Sci. 2016;26:192\u2013204."}, {"Citation": "Sayehmiri K, Tardeh Z, Mansouri A, Borji M, Azami M. The prevalence of hypogonadism in patients with thalassemia major in Iran\u2013a systematic review and meta-analysis study. J Shahrekord Univ Med Sci. 2016;18:140\u201351."}, {"Citation": "De Sanctis V, Tangerini A, Testa MR, et al. Final height and endocrine function in thalassaemia intermedia. J Pediatr Endocrinol Metab. 1998;11:965\u201371.", "ArticleIdList": ["10091174"]}, {"Citation": "Sonbolestan M, Mokhtarinejad F, Omrani M. An Evaluation of sensory neural hearing loss in thalassaemic patients treated with desferrioxamine and its risk factors. J Res Med Sci. 2005;10:210\u20136."}, {"Citation": "Shamsian BS, Aminasnafi A, Moghadassian H, et al. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine. Pediatr Hematol Oncol. 2008;25:502\u20138.", "ArticleIdList": ["18728969"]}, {"Citation": "Chahkandi T, Mofatteh MR, Sharifzadeh Gh, Azarkar Z. Hearing impairment in patients with major thalassemia in Southern Khorasan Province, 2007. J Birjand Univ Med Sci. 2011;18:102\u20138."}, {"Citation": "Nili S, Karimi Yazdi AR, Sharifian RA, Jalaei S. Hearing evaluation of thalassemic patients with Desferrioxamine therapy in Qazvin thalassemia center and Tehran pediatrics\u2019 Medical Center. J Audiology. 2002;11:31\u20135."}, {"Citation": "Taziki MH, Golalipour MJ, Behnampour N. The determination of hearing loss in thalassemia major. J Gorgan Univ Med Sci. 2005;6:35\u20139."}, {"Citation": "Kiakojouri K, Tamaddoni A, Mahmoodi Nesheli H, Jahanian Bahnemiri Z, Gholipour S. Correlation of hearing impairment with desferal and serum ferritin level in \u03b2 thalassemia major patients. J Babol Univ Med Sci. 2008;10:48\u201353."}, {"Citation": "Mozafari Nia K, Farahmandi Nia Z, Ghazvini M. Evaluation of hearing threshold in patients with beta thalassemic major receiving regular chelation therapy with Desferrioxamine (DFO) Kerman Univ Med Sci. 2005;12:93\u20138."}, {"Citation": "Azami M, Hafezi Ahmadi MR, Sayehmiri K. Hepatitis B vaccination efficacy in Iranian healthcare workers: a meta-analysis study. Hepat Mon. 2017;17:e37781."}, {"Citation": "Spector TD, Thompson SG. The potential and limitations of meta-analysis. J Epidemiol Community Health. 1991;45:89\u201392.", "ArticleIdList": ["PMC1060723", "2072080"]}, {"Citation": "Azami M, Khataee M, Bigam Bigdeli-Shamlo M, et al. Prevalence and risk factors of hepatitis b infection in pregnant women of Iran: a systematic review and meta-analysis. IJOGI. 2016;19:17\u201330."}, {"Citation": "Azami M, Nasirkandy MP, Mansouri A, et al. Global prevalence of helicobacter pylori infection in pregnant women: a systematic review and meta-analysis study. Int J Women's Health Reprod Sci. 2017;5:30\u20136."}, {"Citation": "Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.", "ArticleIdList": ["19622511"]}, {"Citation": "Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.", "ArticleIdList": ["18064739"]}, {"Citation": "Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646\u201354.", "ArticleIdList": ["16282215"]}, {"Citation": "Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Syn Methods. 2010;1:97\u2013111.", "ArticleIdList": ["26061376"]}, {"Citation": "Ashrafi M, Mohammadzadeh A. Hearing status of thalassemic patients treated with dessfroxamine. Behbood J. 2011;15:365\u201371."}, {"Citation": "Company F, Rezaei N, Yosefi G. Evaluation of hearing loss and otolaryngeal disorders in beta thalassemic patients treated with deferoxamine. Sci J Kurdistan Univ Med Sci. 2009;14:47\u201355."}, {"Citation": "Dousti A, Akhondi R, Atighechi S. Auditory evaluation of patients with major beta thalassemia under treatment with desferrioxamine. J Res Hearing Speech Language. 2014;1:57\u201362."}, {"Citation": "Reissi N, Kargoshaie A. Prevalence of hearing loss in patients with Beta thalassemia major, Hajar hospital of Shahrekord 2002. J Shahrekord Univ Med Sci. 2004;6:31\u20136."}, {"Citation": "Hashemieh M, Kobar Fard F. The incidence of hearing loss among thalassemic patients in Arak city. Arak Univ Med Sci (Rahavard Danesh)1999. 2:38\u201342."}, {"Citation": "Faramarzi A, Karimi M, Heydari ST, Shishegar M, Kaviani M. Frequency of sensory neural hearing loss in major beta-thalassemias in Southern Iran. Iran J Pediatr. 2010;20:308\u201312.", "ArticleIdList": ["PMC3446050", "23056722"]}, {"Citation": "Sonbolestan M, Mokhtarinejad F, Omrani M. An evaluation of sensory neural hearing loss in thalassaemic patients treated with desferrioxamine and its risk factors. J Res Med Sci. 2005;10:210\u20136."}, {"Citation": "Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K. Evaluation of the incidence of sensorineural hearing loss in beta thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol. 2002;108:79\u201383.", "ArticleIdList": ["12187025"]}, {"Citation": "Azizi G, Habibian N. The relationship between sensorineural hearing loss with the use of chelation therapy in patients with B-thalassemia major (Special Medical Center, Tehran, 2006). Thesis. Tehran: Azad University of Medical Sciences; 2008. [in Persian]"}, {"Citation": "Kaviani M, Rekiabi Bana H, Haghshenas M. ENT Complications in Beta thalassemia major.  Iran J Med Sci. 1992;17:55\u20138. Available at:  http://elib.sums.ac.ir/cgi-bin/koha/opac-detail.pl?bib=133000309."}, {"Citation": "Nowruzi F. Hearing disorders caused by chelation therapy in patients with thalassemia major. Thesis. Babol: Babol University of Medical Sciences ; 1995. [in Persian]"}, {"Citation": "Prasansuk S. Incidence/prevalence of sensorineural hearing impairment in Thailand and Southeast Asia. Audiology. 2000;39:207\u201311.", "ArticleIdList": ["10963442"]}, {"Citation": "Tanphaichitr A, Kusuwan T, Limviriyakul S, et al. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin. 2014;38:345\u201350.", "ArticleIdList": ["25051423"]}, {"Citation": "Kong MH, Goh BS, Hamidah A, Zarina AL. The Prevalence of Sensorineural Hearing Loss in \u03b2-thalassaemia patient treated with Desferrioxamine. Med J Malaysia. 2014;69:9\u201312.", "ArticleIdList": ["24814621"]}, {"Citation": "Kontzoylou G, Koussi A, Economou M, et al. Long term audiological evaluation of beta-thalassemia patients. Acta Otorhinolaryngol Belg. 2004;58:113\u20137.", "ArticleIdList": ["15515654"]}, {"Citation": "Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N. Sensorineural hearing loss in \u03b2-thalassemia patients treated with iron chelation. Ear Nose Throat J. 2015;94:481\u20135.", "ArticleIdList": ["26670754"]}, {"Citation": "Chen SH, Liang DC, Lin HC, et al. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol. 2005;27:651\u20133.", "ArticleIdList": ["16344669"]}, {"Citation": "Ambrosetti U, Dond\u00e8 E, Piatti G, Cappellini MD. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res. 2000;42:485\u20137.", "ArticleIdList": ["11023713"]}, {"Citation": "Onerci M, Aslan S, Gumruk F, et al. Audiologic and impedancemetric findings within thalassaemic patients. Int J Pediatr Otorhinolaryngol. 1994;28:167\u201372.", "ArticleIdList": ["8157415"]}, {"Citation": "Azami M, Nikpay S, Abangah G, Sayehmiri K. Evaluation of the incidence of splenectomy and frequency of regular iron chelation therapy in patients with thalassemia Major in Iran: a meta-analysis. Sci J Iran Blood Transfus Organ. 2016;13:146\u201355."}, {"Citation": "Azami M, Rahmati S, Sayehmiri K. Prevalence of Hyperparathyroidism in Patients with Thalassemia Major in Iran. J Babol Univ Med Sci. 2016;18:39\u201348."}, {"Citation": "Sayehmiri K, Sharifi Sh, Noruzi S, Mansouri A, Azami M. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran-a meta-analysis. Caspian J Intern Med. 2017;8:1\u201315.", "ArticleIdList": ["PMC5412243", "28503277"]}, {"Citation": "Azami M, Parizad N, Kourosh Sayehmiri K. Prevalence of hypothyroidism, hypoparathyroidism and the frequency of regular chelation therapy in patients with thalassemia major in Iran: a systematic review and meta-analysis study. Iran J Ped Hematol Oncol. 2016;6:260\u201375."}, {"Citation": "Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403\u20139.", "ArticleIdList": ["2605127"]}, {"Citation": "De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child. 1988;63:250\u20135.", "ArticleIdList": ["PMC1778769", "3355204"]}, {"Citation": "Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Pediatr Otorhinolaryngol. 1996;35:223\u201330.", "ArticleIdList": ["8762595"]}]}], "History": [{"Year": "2017", "Month": "12", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "12", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "12", "Day": "5", "Hour": "6", "Minute": "1"}, {"Year": "2017", "Month": "9", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29201313", "PMC5686301", "10.22088/cjim.8.4.239"]}}]}